Biotech - SiliconSnark

SiliconSnark robot guides glowing gene editors through a Boston-shaped blood-vessel model.

Boston Tech

Mass General Got $25.8 Million to Send Gene Editors Into Blood Vessels

Mass General won up to $25.8 million from ARPA-H to build a reusable gene-editing platform for rare vascular diseases in Boston and beyond for patients.

SiliconSnark robot in Kendall Square beside a giant CPAP mask and an AD109 pill heading toward FDA review.

Boston Tech

Apnimed Got Its Sleep Apnea Pill Into FDA Review, and Cambridge Sees a CPAP Exit Ramp

Apnimed's July 14 FDA filing acceptance puts its Cambridge sleep apnea pill AD109 on track for a February 28, 2027 review decision.

SiliconSnark robot outside a Cambridge biotech office juggling an antibiotic bottle, antibodies, and financing papers.

Boston Tech

Spero Turned an Antibiotic Approval Into an Immunology Pivot, Because Cambridge Never Wastes a Receipt

Spero Therapeutics used a $105 million royalty financing and a new antibody license to turn its Utebzi approval into a Cambridge immunology reboot.

SiliconSnark robot outside Biogen in Cambridge with a giant autoinjector and home-treatment imagery.

Boston Tech

Biogen Got an At-Home Leqembi Start Approved, and Cambridge Just Shortened the Infusion Pilgrimage

FDA approved Leqembi IQLIK's at-home starting dose on July 13, giving Cambridge-based Biogen a meaningful Alzheimer's access and workflow win.

Mustard-yellow SiliconSnark robot in Kendall Square between Prime and Beam with a gene-editing legal ruling.

Boston Tech

Prime Medicine Beat Beam in Gene-Editing Arbitration, and Cambridge Called It Family Therapy

Prime Medicine's July 8 Beam ruling cleared its AATD gene-editing program, giving Cambridge biotech one more extremely local way to compete.

SiliconSnark robot outside Vertex in Boston juggling a giant biotech deal with drug assets and deal papers.

Boston Tech

Vertex Bought Crinetics for $10 Billion, Because Boston Enjoys Expensive Homework

Vertex agreed to buy Crinetics for $10 billion on July 6, giving Boston biotech a huge endocrinology bet and a fresh test beyond cystic fibrosis.

SiliconSnark robot outside Vertex in Boston presenting a glowing CRISPR plan beside a pediatric treatment wagon.

Boston Tech

Vertex Expanded Casgevy to Age 2, and Boston's CRISPR Future Now Comes in Toddler Sizes

Vertex's July 1 FDA expansion makes Casgevy available to children ages 2 and up, a major Boston biotech milestone with real access hurdles.

SiliconSnark robot in Cambridge flips a giant transcription-factor switch outside a biotech lab.

Boston Tech

Flare Therapeutics Raised $85 Million to Drug Transcription Factors, Which Is Extremely Cambridge

Cambridge-based Flare Therapeutics raised $85 million on June 30 to push a first-in-class prostate cancer program after years of transcription-factor homework.

SiliconSnark robot rolls a glowing drug-application binder outside a Waltham biotech campus.

Boston Tech

Cogent Filed Its Third Bezuclastinib NDA, and Waltham Looks Weirdly Inevitable

Waltham-based Cogent filed an NDA for bezuclastinib in advanced systemic mastocytosis, turning a rare-disease bet into a serious 2026 launch race.

SiliconSnark robot in Kendall Square holding an mRNA-6007 vial as giant immune cells float above Cambridge labs.

Boston Tech

Moderna Put CAR-T in a Vial, and Cambridge Called It a Platform

Cambridge-based Moderna unveiled mRNA-6007, an in vivo CAR-T bet on lupus and related autoimmune disease that could make cell therapy less bespoke.

SiliconSnark robot welcomes a giant AbbVie check outside a Waltham biotech building after the Apogee deal.

Boston Tech

AbbVie Bought Apogee for $10.9 Billion Because Waltham Made Eczema Dosing Less Annoying

AbbVie is buying Waltham-based Apogee for $10.9 billion, turning a long-acting eczema antibody into Boston biotech's latest serious exit.

SiliconSnark robot escorts an IV pole out of a futuristic Kendall Square clinic after Spero's oral antibiotic approval.

Boston Tech

Spero Therapeutics Won FDA Approval for an Oral Carbapenem. Cambridge Just Sent the IV Pole Home.

Spero Therapeutics won FDA approval for the first oral carbapenem in the U.S., giving Cambridge biotech a real answer to hospital-only UTI care.

See all